AI Portfolio Summary
In 2025 Q4, Knott David M Jr maintained a portfolio of 100 distinct positions. The most significant new addition to the portfolio was Cogent Biosciences I, which now represents 1.68% of the total fund value. They heavily accumulated shares in Viridian Therapeutic, increasing their position by 24.4%. The fund also reduced its exposure to Janus Henderson AAA by 78.6%.
Total Positions
100
Quarter
2025 Q4
Top Holding
CLMT (20.4%)
Top 10 Concentration
70.7%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-50 of 100
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
CLMT
Calumet, Inc.
|
Basic Materials | 20.38% | 20.79% |
#1
Prev: #1
|
6.0 | -610,262 | -21.6% |
P
S
|
2,214,969 | $44,011,434 | 2021 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
APO
Apollo Global M...
|
Financial Services | 15.08% | 12.09% |
#2
Prev: #2
|
6.5 | no change | no change |
P
S
|
225,000 | $32,571,000 | 2021 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
GOOG
Alphabet Inc-Cl...
|
Communication Services | 13.28% | 11.02% |
#3
Prev: #3
|
5.5 | -20,800 | -18.5% |
P
S
|
91,420 | $28,687,596 | 2021 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SNDX
Syndax Pharmace...
|
Healthcare | 4.04% | 2.66% |
#4
3
Prev: #7
|
2.6 | -13,000 | -3.0% |
P
S
|
415,000 | $8,719,150 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
XERS
Xeris Biopharma...
|
Healthcare | 3.53% | 3.33% |
#5
1
Prev: #6
|
2.4 | -45,000 | -4.4% |
P
S
|
970,000 | $7,614,500 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TVTX
Travere Therape...
|
Healthcare | 3.29% | 2.51% |
#6
3
Prev: #9
|
1.3 | -74,000 | -28.5% |
P
S
|
186,000 | $7,107,060 | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BBIO
Bridgebio Pharm...
|
Healthcare | 3.01% | 1.78% |
#7
5
Prev: #12
|
2.2 | no change | no change |
P
S
|
85,000 | $6,501,650 | 2022 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PTGX
Protagonist The...
|
Healthcare | 2.95% | 2.22% |
#8
3
Prev: #11
|
1.7 | -10,000 | -12.0% |
P
S
|
73,000 | $6,375,820 | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
JPM
JPMorgan Chase ...
|
Financial Services | 2.91% | 2.59% |
#9
1
Prev: #8
|
1.7 | -897 | -4.4% |
P
S
|
19,477 | $6,275,879 | 2021 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
JAAA
Janus Henderson...
|
ETF | 2.19% | 8.96% |
#10
6
Prev: #4
|
0.9 | -344,226 | -78.6% |
P
S
|
93,528 | $4,730,646 | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VRDN
Viridian Therap...
|
Healthcare | 2.09% | 1.01% |
#11
7
Prev: #18
|
3.3 | 28,426 | 24.4% |
P
S
|
145,000 | $4,512,400 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CPRX
Catalyst Pharma...
|
Healthcare | 2.04% | 1.50% |
#12
4
Prev: #16
|
1.8 | no change | no change |
P
S
|
189,000 | $4,411,260 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
COGT
Cogent Bioscien...
|
Healthcare | 1.68% | — |
#13
Prev: #—
|
4.2 | 102,000 | no change |
NEW
|
102,000 | $3,623,040 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RCUS
Arcus Bioscienc...
|
Healthcare | 1.34% | 0.52% |
#14
14
Prev: #28
|
3.0 | 26,041 | 27.4% |
P
S
|
121,241 | $2,889,173 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ALKS
Alkermes PLC
|
Healthcare | 1.23% | 0.23% |
#15
35
Prev: #50
|
3.5 | 75,700 | 392.2% |
P
S
|
95,000 | $2,658,100 | 2023 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DCGO
DocGo, Inc.
|
Healthcare | 1.09% | 1.68% |
#16
3
Prev: #13
|
0.9 | -400,000 | -13.0% |
P
S
|
2,670,850 | $2,344,472 | 2021 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CYBN
Cybin Inc
|
Healthcare | 1.08% | 0.33% |
#17
22
Prev: #39
|
3.4 | 144,940 | 103.3% |
P
S
|
285,182 | $2,332,789 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CYTK
Cytokinetics, I...
|
Healthcare | 1.00% | 0.66% |
#18
7
Prev: #25
|
2.4 | 4,000 | 13.3% |
P
S
|
34,000 | $2,160,360 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ATRC
AtriCure, Inc.
|
Healthcare | 0.94% | 0.68% |
#19
5
Prev: #24
|
2.4 | 3,400 | 7.1% |
P
S
|
51,400 | $2,033,384 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AB
AllianceBernste...
|
Financial Services | 0.86% | 0.74% |
#20
3
Prev: #23
|
1.3 | no change | no change |
P
S
|
48,000 | $1,847,040 | 2021 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ACLX
Arcellx Inc
|
Healthcare | 0.78% | 0.85% |
#21
Prev: #21
|
1.3 | no change | no change |
P
S
|
25,700 | $1,675,640 | 2023 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
XBI
SPDR S&P Biotec...
|
ETF | 0.73% | 0.20% |
#22
30
Prev: #52
|
3.3 | 8,000 | 160.0% |
P
S
|
13,000 | $1,585,090 | 2021 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TECX
Tectonic Therap...
|
Healthcare | 0.71% | 0.47% |
#23
10
Prev: #33
|
1.3 | no change | no change |
P
S
|
74,000 | $1,543,640 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
WVE
Wave Life Scien...
|
Healthcare | 0.71% | 0.27% |
#24
20
Prev: #44
|
1.3 | no change | no change |
P
S
|
90,000 | $1,530,000 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
JNJ
Johnson & Johns...
|
Healthcare | 0.66% | 0.52% |
#25
4
Prev: #29
|
1.3 | no change | no change |
P
S
|
6,922 | $1,432,508 | 2021 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TGTX
TG Therapeutics...
|
Healthcare | 0.62% | — |
#26
Prev: #—
|
3.7 | 45,000 | no change |
NEW
|
45,000 | $1,341,450 | 2021 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VERA
Vera Therapeuti...
|
Healthcare | 0.61% | 0.30% |
#27
13
Prev: #40
|
1.2 | no change | no change |
P
S
|
26,000 | $1,316,640 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CLOZ
The Panagram BB...
|
ETF | 0.59% | 0.52% |
#28
2
Prev: #30
|
1.2 | no change | no change |
P
S
|
47,807 | $1,265,929 | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BHVN
Biohaven LTD
|
Healthcare | 0.58% | — |
#29
Prev: #—
|
3.7 | 110,720 | no change |
NEW
|
110,720 | $1,250,029 | 2022 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BMY
Bristol-Myers S...
|
Healthcare | 0.55% | 0.49% |
#30
1
Prev: #31
|
0.7 | -5,000 | -18.5% |
P
S
|
22,000 | $1,186,680 | 2021 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MDGL
Madrigal Pharma...
|
Healthcare | 0.54% | 0.37% |
#31
6
Prev: #37
|
1.2 | no change | no change |
P
S
|
2,000 | $1,164,680 | 2022 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ADMA
ADMA Biologics,...
|
Healthcare | 0.51% | — |
#32
Prev: #—
|
3.7 | 60,200 | no change |
NEW
|
60,200 | $1,098,048 | 2021 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BIIB
Biogen Inc.
|
Healthcare | 0.49% | 0.11% |
#33
26
Prev: #59
|
3.2 | 4,000 | 200.0% |
P
S
|
6,000 | $1,055,940 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
OBIO
Orchestra Biome...
|
Healthcare | 0.48% | 0.20% |
#34
20
Prev: #54
|
2.7 | 55,000 | 28.2% |
P
S
|
250,000 | $1,037,500 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IBB
iShares Biotech...
|
ETF | 0.43% | 0.26% |
#35
10
Prev: #45
|
2.7 | 1,000 | 22.2% |
P
S
|
5,500 | $928,235 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SLDB
Solid Bioscienc...
|
Healthcare | 0.42% | 0.40% |
#36
1
Prev: #35
|
1.2 | no change | no change |
P
S
|
162,440 | $916,162 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
LENZ
LENZ Therapeuti...
|
Healthcare | 0.40% | 1.54% |
#37
22
Prev: #15
|
0.2 | -28,268 | -34.5% |
P
S
|
53,732 | $859,712 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PFE
Pfizer Inc.
|
Healthcare | 0.37% | 0.77% |
#38
16
Prev: #22
|
0.1 | -42,200 | -56.6% |
P
S
|
32,337 | $805,191 | 2021 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RZLT
Rezolute, Inc.
|
Healthcare | 0.37% | 1.04% |
#39
22
Prev: #17
|
2.6 | 65,000 | 23.6% |
P
S
|
340,000 | $802,400 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MSFT
Microsoft Corpo...
|
Technology | 0.36% | 0.33% |
#40
2
Prev: #38
|
1.1 | no change | no change |
P
S
|
1,600 | $773,792 | 2021 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AAPL
Apple Inc.
|
Technology | 0.31% | 0.26% |
#41
5
Prev: #46
|
1.1 | no change | no change |
P
S
|
2,494 | $678,019 | 2021 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
EOLS
Evolus, Inc.
|
Healthcare | 0.31% | — |
#42
Prev: #—
|
3.6 | 99,338 | no change |
NEW
|
99,338 | $660,598 | 2023 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NKTR
Nektar Therapeu...
|
Healthcare | 0.30% | — |
#43
Prev: #—
|
3.6 | 15,500 | no change |
NEW
|
15,500 | $655,340 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IBM
International B...
|
Technology | 0.29% | 0.24% |
#44
4
Prev: #48
|
1.1 | no change | no change |
P
S
|
2,142 | $634,482 | 2023 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SRRK
Scholar Rock Ho...
|
Healthcare | 0.28% | 0.14% |
#45
13
Prev: #58
|
3.1 | 4,913 | 54.6% |
P
S
|
13,913 | $612,868 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PTHS
Pelthos Therape...
|
Healthcare | 0.28% | 0.07% |
#46
18
Prev: #64
|
3.1 | 13,169 | 215.5% |
P
S
|
19,281 | $597,711 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CNQ
Canadian Natura...
|
Energy | 0.26% | 0.22% |
#47
4
Prev: #51
|
1.1 | no change | no change |
P
S
|
16,800 | $568,680 | 2021 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
N/A
Connect Biophar...
|
—
|
Unknown | 0.26% | — |
#48
Prev: #—
|
3.6 | 200,000 | no change |
NEW
|
200,000 | $564,000 | — | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | ||
|
XENE
Xenon Pharmaceu...
|
Healthcare | 0.23% | 0.18% |
#49
7
Prev: #56
|
1.1 | no change | no change |
P
S
|
10,962 | $491,317 | 2021 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AGIO
Agios Pharmaceu...
|
Healthcare | 0.23% | — |
#50
Prev: #—
|
3.6 | 18,000 | no change |
NEW
|
18,000 | $489,960 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) |
Showing 1-50 of 100 holdings